Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 173 clinical trials
featured
Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma (015-104)

Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma (015-104)

  • 430 views
  • 23 Nov, 2020
  • 1 location
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.

  • 0 views
  • 03 Jul, 2021
  • 18 locations
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type Metastatic Colorectal Cancer

effectiveness of CMAB009 in combination with a standard and effective chemotherapy FOLFIRI5-Fluorouracil /Folinic acid plus Irinotecanfor RAS/BRAF wild-type, metastatic colorectal cancer in first-line setting

adenocarcinoma
metastasis
folfiri regimen
leucovorin
measurable disease
  • 3 views
  • 25 Jan, 2021
  • 2 locations
  • 0 views
  • 04 Aug, 2021
  • 13 locations
Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)

will take place at the time of registration taking into account NF1 and BRAF-KIAA1549-fusion status.

progressive disease
neutrophil count
platelet count
glomerular filtration rate
BRAF
  • 0 views
  • 24 Jan, 2021
  • 24 locations
MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

Open-label, dose-confirmation and cohort expansion, multicentre, Phase Ib/II study to assess the anti-tumour activity and safety of MEN1611 in combination with cetuximab for the treatment of patients with PIK3CA mutated metastatic colorectal cancer.

metastasis
adenocarcinoma
PIK3CA
cetuximab
measurable disease
  • 2 views
  • 27 Jan, 2021
  • 39 locations
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

This study will evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor 2 (HER2)-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC).

  • 0 views
  • 19 Jul, 2021
  • 73 locations
A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

The goal of this trial is to test the safety and efficacy of an innovative combination aimed to more profoundly inhibit ERK signaling in tumors.

  • 0 views
  • 30 May, 2021
  • 6 locations
  • 0 views
  • 08 Jul, 2021
  • 1 location
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

Background Most people with hairy cell leukemia have a BRAF gene mutation. They can be treated with BRAF inhibitors, drugs that target this mutation. For people

  • 0 views
  • 22 Mar, 2021
  • 1 location